Dyslipidemia Drugs Market to Reach US$ 18,212.5 Million by 2030
Author : Ryan Dwas | Published On : 29 Dec 2023
Dyslipidemia is a medical condition characterized by abnormal lipid levels in the blood. Lipids are fats and oils that play a vital role in the proper functioning of the body. These lipids can be classified into several types, such as triglycerides, phospholipids, and cholesterol. If left untreated, dyslipidemia can lead to serious health problems, such as heart disease and stroke. Fortunately, there are several drugs available to treat this condition, including statins, fibrates, and ezetimibe.
The global dyslipidemia drugs market was valued at US$ 13,234.1 Million in 2022 and is anticipated to reach US$ 18,212.5 Million by the end of 2030 with a CAGR of 6.1% from 2023 to 2030.
The dyslipidemia drugs market is a pharmaceutical market that offers a range of drugs to treat high levels of lipids, such as cholesterol, triglycerides, LDL, and HDL, in the blood. Dyslipidemia is a major risk factor for cardiovascular diseases like heart attack and stroke. Drugs such as statins, bile acid sequestrants, fibrates, niacin, and cholesterol absorption inhibitors work to lower lipid levels in the blood, thereby reducing the risk of cardiovascular events. The global dyslipidemia drugs market is expected to grow significantly as the prevalence of dyslipidemia rises, and people become more aware of the importance of controlling lipid levels in the blood.
Some common symptoms of dyslipidemia include leg pain, chest pain, and tightness or pressure in the chest, neck, jaw, shoulders, and back. Other symptoms include indigestion and heartburn, sleep problems, dizziness, heart palpitations, cold sweats, vomiting and nausea, and swelling in the legs, ankles, feet, stomach, and veins of the neck.
Dyslipidemia Drugs Market to Recover Amid COVID-19 Pandemic:
Pharmaceutical and biotech companies, in collaboration with governments worldwide, are actively addressing the COVID-19 outbreak. Their efforts span vaccine development and planning for challenges in the medicine supply chain. Currently, there are approximately 115 vaccine candidates and 155 molecules in the R&D pipeline. Additionally, there has been a significant surge in demand for commonly used drugs like hydroxychloroquine for COVID-19 management. As a result, many developed countries are facing shortages of these drugs, creating substantial opportunities for manufacturers of COVID-19 management drugs. The pharmaceutical and biotechnology industries are expected to experience significant growth in the future due to the demand for COVID-19 vaccines and treatment drugs. These factors indicate that COVID-19 is likely to have a significant impact on the Dyslipidemia drugs market.
Request Sample Copy of this Report: https://cognizancemarketresearch.com/request/dyslipidemia-drugs-market/
Factors Driving the Growth of Dyslipidemia Drugs Market in North America Region:
Dyslipidemia is a common condition affecting more than 100 million adults in North America, with high cholesterol levels being the core symptom. This has led to a significant increase in demand for dyslipidemia drugs in the region.
Obesity is one of the major risk factors for dyslipidemia and the rate of obesity in North America is one of the highest in the world. Over 35% of the adult population in North America is classified as obese, leading to an increased demand for dyslipidemia drugs to manage the associated conditions.
In recent years, there have been several technological advancements in the field of dyslipidemia drugs, including the development of novel drug delivery systems and formulations. These advancements have increased the efficacy and safety of dyslipidemia drugs, thereby driving growth in the market.
North America has one of the highest healthcare expenditures in the world, with a significant portion of this expenditure dedicated to chronic disease management. This has led to greater funding for research and development of dyslipidemia drugs.
There has been a significant increase in awareness and education around the health risks associated with dyslipidemia, including cardiovascular disease. This, coupled with a greater focus on preventative healthcare, has led to an increased demand for dyslipidemia drugs in North America.
About Us
Cognizance market research is continuously guiding customers around the globe towards strategies for transformational growth. Today, businesses have to innovate more than ever before, not just to survive, but to succeed in the future. Customers choose cognizance market research not only to recognize growth opportunities but to help create visionary strategic initiatives for their futures, facilitated by our incredible depth and breadth of strategic leadership, study, resources, events, and expertise that help our customers to achieve their goals.
As the gold standard data provider to the world’s largest industries, to generate the most detailed, authoritative, and granular market information, cognizance market research continuously captures and analyzes terabytes of data. Our unique, human-driven, and technology-powered data-driven approach generates the optimistic, actionable, and forward-looking intelligence you need to forecast the future and avoid blind-spots. We give you access to unrivalled capabilities across one platform, leveraging our unique data, expert insight, and creative solutions.
Contact US
Website - https://cognizancemarketresearch.com/
Facebook - http://facebook.com/cognizancemarketresearch
Youtube - https://www.youtube.com/@cognizancemarketresearch
Linkedin - https://www.linkedin.com/company/cognizance-market-research-cmr
